NeoGenomics, Inc. (NEO)
USD 8.2
(-7.13%)
USD 8.2
(-7.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 739.69 Million USD | -0.31% |
| 2022 | 742.01 Million USD | -2.56% |
| 2021 | 761.5 Million USD | 158.98% |
| 2020 | 294.03 Million USD | 45.49% |
| 2019 | 202.09 Million USD | 9.5% |
| 2018 | 184.57 Million USD | 33.94% |
| 2017 | 137.8 Million USD | -8.45% |
| 2016 | 150.52 Million USD | 15.93% |
| 2015 | 129.84 Million USD | 527.23% |
| 2014 | 20.7 Million USD | 13.71% |
| 2013 | 18.2 Million USD | -12.71% |
| 2012 | 20.85 Million USD | 48.41% |
| 2011 | 14.05 Million USD | 33.62% |
| 2010 | 10.51 Million USD | 44.02% |
| 2009 | 7.3 Million USD | 26.02% |
| 2008 | 5.79 Million USD | 38.0% |
| 2007 | 4.19 Million USD | 36.44% |
| 2006 | 3.07 Million USD | 48.31% |
| 2005 | 2.07 Million USD | 103.7% |
| 2004 | 1.01 Million USD | 16.44% |
| 2003 | 874.84 Thousand USD | 106.09% |
| 2002 | 424.49 Thousand USD | 127.96% |
| 2001 | 186.21 Thousand USD | 48.94% |
| 2000 | 125.02 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 716.92 Million USD | -3.08% |
| 2024 Q3 | 732.9 Million USD | 0.76% |
| 2024 Q2 | 727.39 Million USD | 1.46% |
| 2023 FY | 739.69 Million USD | -0.31% |
| 2023 Q2 | 738.91 Million USD | 0.57% |
| 2023 Q3 | 730.81 Million USD | -1.1% |
| 2023 Q1 | 734.71 Million USD | -0.98% |
| 2023 Q4 | 739.69 Million USD | 1.21% |
| 2022 Q1 | 754.54 Million USD | -0.91% |
| 2022 Q2 | 748.59 Million USD | -0.79% |
| 2022 Q3 | 742.59 Million USD | -0.8% |
| 2022 Q4 | 742.01 Million USD | -0.08% |
| 2022 FY | 742.01 Million USD | -2.56% |
| 2021 Q1 | 650.69 Million USD | 121.3% |
| 2021 Q2 | 747.95 Million USD | 14.95% |
| 2021 Q3 | 769.14 Million USD | 2.83% |
| 2021 Q4 | 761.5 Million USD | -0.99% |
| 2021 FY | 761.5 Million USD | 158.98% |
| 2020 Q4 | 294.03 Million USD | 0.33% |
| 2020 Q3 | 293.06 Million USD | 0.62% |
| 2020 Q1 | 227.2 Million USD | 12.42% |
| 2020 FY | 294.03 Million USD | 45.49% |
| 2020 Q2 | 291.25 Million USD | 28.19% |
| 2019 Q2 | 206.93 Million USD | -1.22% |
| 2019 Q1 | 209.49 Million USD | 13.5% |
| 2019 Q3 | 214.14 Million USD | 3.49% |
| 2019 Q4 | 202.09 Million USD | -5.63% |
| 2019 FY | 202.09 Million USD | 9.5% |
| 2018 Q3 | 151.58 Million USD | -16.52% |
| 2018 FY | 184.57 Million USD | 33.94% |
| 2018 Q2 | 181.57 Million USD | 28.54% |
| 2018 Q1 | 141.25 Million USD | 2.5% |
| 2018 Q4 | 184.57 Million USD | 21.77% |
| 2017 Q3 | 144.23 Million USD | 0.65% |
| 2017 Q4 | 137.8 Million USD | -4.46% |
| 2017 FY | 137.8 Million USD | -8.45% |
| 2017 Q1 | 156.17 Million USD | 3.75% |
| 2017 Q2 | 143.3 Million USD | -8.24% |
| 2016 Q1 | 106.67 Million USD | -17.85% |
| 2016 FY | 150.52 Million USD | 15.93% |
| 2016 Q4 | 150.52 Million USD | 37.67% |
| 2016 Q3 | 109.33 Million USD | 1.06% |
| 2016 Q2 | 108.18 Million USD | 1.42% |
| 2015 Q3 | 21.89 Million USD | -0.94% |
| 2015 Q4 | 129.84 Million USD | 493.11% |
| 2015 Q2 | 22.09 Million USD | 5.22% |
| 2015 Q1 | 21 Million USD | 1.46% |
| 2015 FY | 129.84 Million USD | 527.23% |
| 2014 Q3 | 19.75 Million USD | -3.66% |
| 2014 Q2 | 20.5 Million USD | 3.44% |
| 2014 Q4 | 20.7 Million USD | 4.79% |
| 2014 FY | 20.7 Million USD | 13.71% |
| 2014 Q1 | 19.82 Million USD | 8.89% |
| 2013 FY | 18.2 Million USD | -12.71% |
| 2013 Q4 | 18.2 Million USD | 22.16% |
| 2013 Q3 | 14.9 Million USD | -0.77% |
| 2013 Q2 | 15.01 Million USD | 1.58% |
| 2013 Q1 | 14.78 Million USD | -29.1% |
| 2012 FY | 20.85 Million USD | 48.41% |
| 2012 Q1 | 17.77 Million USD | 26.46% |
| 2012 Q4 | 20.85 Million USD | 3.86% |
| 2012 Q2 | 18.28 Million USD | 2.88% |
| 2012 Q3 | 20.08 Million USD | 9.83% |
| 2011 FY | 14.05 Million USD | 33.62% |
| 2011 Q4 | 14.05 Million USD | 15.89% |
| 2011 Q3 | 12.12 Million USD | 6.65% |
| 2011 Q2 | 11.36 Million USD | 13.53% |
| 2011 Q1 | 10.01 Million USD | -4.77% |
| 2010 Q3 | 10.9 Million USD | 6.21% |
| 2010 FY | 10.51 Million USD | 44.02% |
| 2010 Q1 | 9.11 Million USD | 24.83% |
| 2010 Q4 | 10.51 Million USD | -3.58% |
| 2010 Q2 | 10.26 Million USD | 12.65% |
| 2009 Q1 | 6.52 Million USD | 12.59% |
| 2009 FY | 7.3 Million USD | 26.02% |
| 2009 Q2 | 7.03 Million USD | 7.82% |
| 2009 Q3 | 5.86 Million USD | -16.55% |
| 2009 Q4 | 7.3 Million USD | 24.4% |
| 2008 Q4 | 5.79 Million USD | 4.58% |
| 2008 Q2 | 5.33 Million USD | 31.11% |
| 2008 Q1 | 4.06 Million USD | -3.09% |
| 2008 FY | 5.79 Million USD | 38.0% |
| 2008 Q3 | 5.54 Million USD | 3.86% |
| 2007 Q2 | 2.16 Million USD | -37.89% |
| 2007 Q1 | 3.48 Million USD | 13.16% |
| 2007 Q4 | 4.19 Million USD | 70.65% |
| 2007 FY | 4.19 Million USD | 36.44% |
| 2007 Q3 | 2.46 Million USD | 13.76% |
| 2006 Q1 | 2.29 Million USD | 10.66% |
| 2006 Q3 | 2.74 Million USD | 13.04% |
| 2006 Q2 | 2.42 Million USD | 5.73% |
| 2006 Q4 | 3.07 Million USD | 12.13% |
| 2006 FY | 3.07 Million USD | 48.31% |
| 2005 Q3 | 1.7 Million USD | 32.67% |
| 2005 FY | 2.07 Million USD | 103.7% |
| 2005 Q1 | 1.05 Million USD | 3.54% |
| 2005 Q2 | 1.28 Million USD | 21.6% |
| 2005 Q4 | 2.07 Million USD | 21.95% |
| 2004 Q3 | 893.77 Thousand USD | -9.6% |
| 2004 FY | 1.01 Million USD | 16.44% |
| 2004 Q2 | 988.66 Thousand USD | -3.15% |
| 2004 Q4 | 1.01 Million USD | 13.97% |
| 2004 Q1 | 1.02 Million USD | 16.69% |
| 2003 Q4 | 874.84 Thousand USD | 23.59% |
| 2003 Q1 | 559.68 Thousand USD | 31.85% |
| 2003 FY | 874.84 Thousand USD | 106.09% |
| 2003 Q2 | 583.97 Thousand USD | 4.34% |
| 2003 Q3 | 707.88 Thousand USD | 21.22% |
| 2002 Q3 | 374.09 Thousand USD | -18.43% |
| 2002 Q2 | 458.6 Thousand USD | 15.33% |
| 2002 FY | 424.49 Thousand USD | 127.96% |
| 2002 Q1 | 397.64 Thousand USD | 113.54% |
| 2002 Q4 | 424.49 Thousand USD | 13.47% |
| 2001 FY | 186.21 Thousand USD | 48.94% |
| 2001 Q4 | 186.21 Thousand USD | -18.12% |
| 2001 Q3 | 227.41 Thousand USD | -29.67% |
| 2001 Q1 | 470.16 Thousand USD | 276.04% |
| 2001 Q2 | 323.34 Thousand USD | -31.23% |
| 2000 Q3 | 552.24 Thousand USD | 30.84% |
| 2000 Q1 | 336.84 Thousand USD | 0.0% |
| 2000 FY | 125.02 Thousand USD | 0.0% |
| 2000 Q4 | 125.02 Thousand USD | -77.36% |
| 2000 Q2 | 422.08 Thousand USD | 25.31% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1738.841% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -8325.539% |
| Aspira Women's Health Inc. | 8.62 Million USD | -8474.151% |
| Biodesix, Inc. | 94.51 Million USD | -682.61% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -42363.666% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -21873.462% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -21873.462% |
| Bionano Genomics, Inc. | 118.24 Million USD | -525.548% |
| CareDx, Inc | 223.28 Million USD | -231.274% |
| Check-Cap Ltd. | 1.33 Million USD | -55515.94% |
| Castle Biosciences, Inc. | 86.54 Million USD | -754.72% |
| DarioHealth Corp. | 38.24 Million USD | -1834.088% |
| Exact Sciences Corporation | 3.32 Billion USD | 77.761% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -429.02% |
| Guardant Health, Inc. | 1.62 Billion USD | 54.557% |
| ICON Public Limited Company | 7.74 Billion USD | 90.455% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 58.336% |
| Illumina, Inc. | 4.36 Billion USD | 83.058% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -13119.002% |
| iSpecimen Inc. | 6.07 Million USD | -12069.87% |
| Standard BioTools Inc. | 159.86 Million USD | -362.698% |
| MDxHealth SA | 121.92 Million USD | -506.683% |
| 23andMe Holding Co. | 206.64 Million USD | -257.95% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 32.625% |
| Myriad Genetics, Inc. | 312.9 Million USD | -136.399% |
| Mainz Biomed B.V. | 12.15 Million USD | -5983.092% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -67442.097% |
| Neogen Corporation | 1.44 Billion USD | 48.633% |
| Inotiv, Inc. | 588.04 Million USD | -25.789% |
| Natera, Inc. | 691.79 Million USD | -6.923% |
| OpGen, Inc. | 13.44 Million USD | -5402.081% |
| OPKO Health, Inc. | 622.47 Million USD | -18.83% |
| Psychemedics Corporation | 6.59 Million USD | -11110.852% |
| Prenetics Global Limited | 44.01 Million USD | -1580.612% |
| Prenetics Global Limited | 44.01 Million USD | -1580.612% |
| Precipio, Inc. | 3.67 Million USD | -20044.118% |
| Personalis, Inc. | 95.65 Million USD | -673.267% |
| RadNet, Inc. | 2.07 Billion USD | 64.324% |
| Sera Prognostics, Inc. | 25.28 Million USD | -2825.65% |
| Sotera Health Company | 2.68 Billion USD | 72.468% |
| Neuronetics, Inc. | 81.64 Million USD | -806.03% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -3312.651% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -3312.651% |
| Trinity Biotech plc | 83.38 Million USD | -787.091% |
| T2 Biosystems, Inc. | 62.83 Million USD | -1077.235% |
| Twist Bioscience Corporation | 152.97 Million USD | -383.55% |
| Exagen Inc. | 34.25 Million USD | -2059.685% |